2023. CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s174. DOI:https://doi.org/10.25251/skin.7.supp.174.